Natural compound Alternol exerts a broad anti-cancer spectrum and a superior therapeutic safety index

Alternol anti-cancer drug natural compound ovarian cancer prostate cancer

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 30 03 2024
accepted: 06 05 2024
medline: 10 6 2024
pubmed: 10 6 2024
entrez: 10 6 2024
Statut: epublish

Résumé

Alternol is a natural compound isolated from the fermentation of a mutated fungus. We have demonstrated its potent anti-cancer effect We first tested its anti-cancer spectrum using the National Cancer Institute-60 (NCI-60) screening, a protein quantitation-based assay. CellTiter-Glo screening was utilized for ovarian cancer cell lines. Cell cycle distribution was analyzed using flow cytometry. Xenograft models in nude mice were used to assess anti-cancer effect. Healthy mice were tested for the acuate systemic toxicity. Our results showed that Alternol exerted a potent anti-cancer effect on 50 (83%) cancer cell lines with a GI Taken together, Alternol has a broad anti-cancer spectrum with a safe therapeutic index

Identifiants

pubmed: 38855749
doi: 10.3389/fphar.2024.1409506
pii: 1409506
pmc: PMC11157072
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1409506

Informations de copyright

Copyright © 2024 He, Ma, Hirst, Li, Wu, Liu, Zhao, Xu, Godwin, Wang and Li.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Chenchen He (C)

Department of Radiation Oncology, The First Affiliated Hospital of Xi'An Jiaotong University, Xi'An, China.
Department of Urology, The University of Kansas Medical Center, Kansas City, KS, United States.

Linlin Ma (L)

Department of Urology, The University of Kansas Medical Center, Kansas City, KS, United States.

Jeff Hirst (J)

Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.

Fei Li (F)

Department of Physiology, Shenyang Pharmaceutical University, Shenyang, China.

Hao Wu (H)

Department of Physiology, Shenyang Pharmaceutical University, Shenyang, China.

Wang Liu (W)

Department of Urology, The University of Kansas Medical Center, Kansas City, KS, United States.

Jiang Zhao (J)

Department of Urology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.

Feng Xu (F)

Department of Physiology, Shenyang Pharmaceutical University, Shenyang, China.

Andrew K Godwin (AK)

Department of Radiation Oncology, The First Affiliated Hospital of Xi'An Jiaotong University, Xi'An, China.
Department of Urology, The University of Kansas Medical Center, Kansas City, KS, United States.
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
Department of Physiology, Shenyang Pharmaceutical University, Shenyang, China.
Department of Urology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.

Xiangwei Wang (X)

Department of Urology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.

Benyi Li (B)

Department of Urology, The University of Kansas Medical Center, Kansas City, KS, United States.

Classifications MeSH